Ask AI

Challenging Treatment Paradigms in HER2-Low and HER2-Ultralow MBC: Experts Examine The Evidence to Guide Individualized Clinical Decisions

Experts insight on caring for patients with HER2-low and HER2-ultralow metastatic breast cancer using HER2-targeted therapy based on recent clinical data through an ASCO satellite symposium, a certified on-demand webcast, expert-written ClinicalThought commentaries, and accompanying downloadable slides.

Share

Program Content

Activities

ADC Safety in mBC
Maximizing Safety and Efficacy of ADCs in Patients With HER2-Low or Ultralow mBC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 20, 2025

Expires: November 19, 2025

Treatment for HER2-Low/Ultralow mBC
Selecting Treatment for HER2-Low/Ultralow mBC After Progression on ET
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 22, 2025

Expires: November 21, 2025

Assessing HER2 Low and Ultralow mBC
HER2 Assessment and Testing in 2025: What HCPs Need to Know
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 23, 2025

Expires: November 22, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.